Last reviewed · How we verify
NCT03346967: MSCSHD
Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency
Phase 1, PHASE2 trial testing adipose-derived mesenchymal stem cells in Hormone Deficiency in 30 participants. Completed in 30 March 2020.
28 February 2020
Quick facts
| Lead sponsor | Vinmec Research Institute of Stem Cell and Gene Technology |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 November 2017 |
| Primary completion | 28 February 2020 |
| Estimated completion | 30 March 2020 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- adipose-derived mesenchymal stem cells — full drug profile →
Conditions studied
- Hormone Deficiency — all drugs for Hormone Deficiency →
Sponsor
Vinmec Research Institute of Stem Cell and Gene Technology
Who can join
Adults 35 to 70, any sex, with Hormone Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and effectiveness of adipose derived mesenchymal stem cells (AD-MSCs) therapy on sexual hormone deficiency in the middle-aged patients
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Can Autologous Adipose-Derived Mesenchymal Stem Cell Transplantation Improve Sexual Function in People with Sexual Functional Deficiency?
Nguyen Thanh L, Dam PTM, Nguyen HP, Nguyen TT, et al · · 2021 · cited 15× · PMID 34129158 · DOI 10.1007/s12015-021-10196-w -
Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.
Wang J, Zhang M, Wang H. · · 2024 · cited 13× · PMID 39144566 · DOI 10.1021/acsptsci.4c00284
Verify or expand the search:
- PubMed search for NCT03346967
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hormone Deficiency
Currently open trials in the same condition.
- NCT04460872 — Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury · Phase 2 · recruiting
Other Vinmec Research Institute of Stem Cell and Gene Technology trials
Trials by the same sponsor.
- NCT07472270 — Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment · Phase 1 · not yet recruiting
- NCT06629324 — Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia · Phase 2 · recruiting
- NCT06726538 — Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Func · Phase 1, PHASE2 · completed
- NCT06027957 — CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia · Phase 1 · completed
- NCT05329662 — Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03346967 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vinmec Research Institute of Stem Cell and Gene Technology
- Last refreshed: 4 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03346967.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing